S&P 500   3,380.34 (+1.40%)
DOW   27,976.55 (+1.05%)
QQQ   272.01 (+2.57%)
AAPL   451.98 (+3.31%)
MSFT   209.13 (+2.83%)
FB   260.43 (+1.68%)
GOOGL   1,507.58 (+1.83%)
AMZN   3,163.51 (+2.69%)
NVDA   456.64 (+5.22%)
CGC   17.26 (+1.83%)
BABA   255.05 (+2.67%)
TSLA   1,552.40 (+12.95%)
GE   6.73 (-0.30%)
MU   48.57 (+1.70%)
AMD   82.48 (+7.28%)
T   30.19 (-0.03%)
F   7.10 (-1.80%)
ACB   9.82 (-2.00%)
GILD   68.79 (+1.01%)
NFLX   475.77 (+1.89%)
DIS   131.76 (+0.97%)
BAC   26.70 (-0.82%)
BA   175.65 (-2.49%)
S&P 500   3,380.34 (+1.40%)
DOW   27,976.55 (+1.05%)
QQQ   272.01 (+2.57%)
AAPL   451.98 (+3.31%)
MSFT   209.13 (+2.83%)
FB   260.43 (+1.68%)
GOOGL   1,507.58 (+1.83%)
AMZN   3,163.51 (+2.69%)
NVDA   456.64 (+5.22%)
CGC   17.26 (+1.83%)
BABA   255.05 (+2.67%)
TSLA   1,552.40 (+12.95%)
GE   6.73 (-0.30%)
MU   48.57 (+1.70%)
AMD   82.48 (+7.28%)
T   30.19 (-0.03%)
F   7.10 (-1.80%)
ACB   9.82 (-2.00%)
GILD   68.79 (+1.01%)
NFLX   475.77 (+1.89%)
DIS   131.76 (+0.97%)
BAC   26.70 (-0.82%)
BA   175.65 (-2.49%)
S&P 500   3,380.34 (+1.40%)
DOW   27,976.55 (+1.05%)
QQQ   272.01 (+2.57%)
AAPL   451.98 (+3.31%)
MSFT   209.13 (+2.83%)
FB   260.43 (+1.68%)
GOOGL   1,507.58 (+1.83%)
AMZN   3,163.51 (+2.69%)
NVDA   456.64 (+5.22%)
CGC   17.26 (+1.83%)
BABA   255.05 (+2.67%)
TSLA   1,552.40 (+12.95%)
GE   6.73 (-0.30%)
MU   48.57 (+1.70%)
AMD   82.48 (+7.28%)
T   30.19 (-0.03%)
F   7.10 (-1.80%)
ACB   9.82 (-2.00%)
GILD   68.79 (+1.01%)
NFLX   475.77 (+1.89%)
DIS   131.76 (+0.97%)
BAC   26.70 (-0.82%)
BA   175.65 (-2.49%)
S&P 500   3,380.34 (+1.40%)
DOW   27,976.55 (+1.05%)
QQQ   272.01 (+2.57%)
AAPL   451.98 (+3.31%)
MSFT   209.13 (+2.83%)
FB   260.43 (+1.68%)
GOOGL   1,507.58 (+1.83%)
AMZN   3,163.51 (+2.69%)
NVDA   456.64 (+5.22%)
CGC   17.26 (+1.83%)
BABA   255.05 (+2.67%)
TSLA   1,552.40 (+12.95%)
GE   6.73 (-0.30%)
MU   48.57 (+1.70%)
AMD   82.48 (+7.28%)
T   30.19 (-0.03%)
F   7.10 (-1.80%)
ACB   9.82 (-2.00%)
GILD   68.79 (+1.01%)
NFLX   475.77 (+1.89%)
DIS   131.76 (+0.97%)
BAC   26.70 (-0.82%)
BA   175.65 (-2.49%)
Log in

NASDAQ:PRQRProQR Therapeutics Stock Price, Forecast & News

$5.30
-0.37 (-6.53 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.07
Now: $5.30
$5.74
50-Day Range
$4.85
MA: $5.40
$6.46
52-Week Range
$4.46
Now: $5.30
$10.98
Volume8,397 shs
Average Volume188,345 shs
Market Capitalization$263.65 million
P/E RatioN/A
Dividend YieldN/A
Beta0.45
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. It is also developing QRX-1011, a single-stranded oligonucleotide for Stargards disease; QRX-704, an oligonucleotide for the treatment of Huntington's disease; and QRX-504 to treat Fuchs' endothelial corneal dystrophy type 3, as well as AT-010, a program for hereditary cerebral hemorrhage with amyloidosis of the Dutch type. The company has a research collaboration agreement with Galapagos N.V. to apply Axiomer, a RNA Editing Technology Platform for various fibrosis targets; and a collaboration agreement with EB Research Partnership and EB Medical Research Foundation to develop QR-313 for patients with dystrophic epidermolysis bullosa. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.
Read More
ProQR Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.11 per share

Profitability

Net Income$-63,560,000.00

Miscellaneous

Employees118
Market Cap$263.65 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$5.30
-0.37 (-6.53 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

How has ProQR Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

ProQR Therapeutics' stock was trading at $7.00 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRQR stock has decreased by 24.3% and is now trading at $5.30.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of ProQR Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for ProQR Therapeutics
.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for ProQR Therapeutics
.

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics NV (NASDAQ:PRQR) announced its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.23.
View ProQR Therapeutics' earnings history
.

What price target have analysts set for PRQR?

3 analysts have issued 12 month price objectives for ProQR Therapeutics' shares. Their forecasts range from $20.00 to $40.00. On average, they expect ProQR Therapeutics' share price to reach $26.67 in the next twelve months. This suggests a possible upside of 403.1% from the stock's current price.
View analysts' price targets for ProQR Therapeutics
.

Has ProQR Therapeutics been receiving favorable news coverage?

News headlines about PRQR stock have been trending negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ProQR Therapeutics earned a news sentiment score of -2.2 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
View the latest news about ProQR Therapeutics
.

Are investors shorting ProQR Therapeutics?

ProQR Therapeutics saw a drop in short interest in February. As of February 15th, there was short interest totaling 596,300 shares, a drop of 18.2% from the January 31st total of 729,000 shares. Based on an average daily trading volume, of 277,900 shares, the days-to-cover ratio is presently 2.1 days.
View ProQR Therapeutics' Short Interest
.

Who are some of ProQR Therapeutics' key competitors?

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include Bioamber (BIOA), GALAPAGOS NV/S (GLPG), Corbus Pharmaceuticals (CRBP), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Uniqure (QURE), TG Therapeutics (TGTX), Viking Therapeutics (VKTX) and Galmed Pharmaceuticals (GLMD).

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the following people:
  • Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 36)
  • Ms. Smital Shah, Chief Bus. & Financial Officer (Age 43)
  • Ms. Lisa A. Hayes, VP of Investor Relations & Corp. Communications
  • Mr. Bart Klein, Sr. VP of Intellectual Property
  • Mr. Gerard Platenburg, Chief Innovation Officer & Chairman of Advisory Board (Age 55)

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Jennison Associates LLC (5.28%), California Public Employees Retirement System (0.17%), Alps Advisors Inc. (0.14%) and Trexquant Investment LP (0.02%).

Which institutional investors are buying ProQR Therapeutics stock?

PRQR stock was purchased by a variety of institutional investors in the last quarter, including Alps Advisors Inc., California Public Employees Retirement System, Jennison Associates LLC, and Trexquant Investment LP.

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $5.30.

How big of a company is ProQR Therapeutics?

ProQR Therapeutics has a market capitalization of $263.65 million. The biopharmaceutical company earns $-63,560,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. ProQR Therapeutics employs 118 workers across the globe.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is www.proqr.com.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.